Published in Cytometry on September 01, 1996
A flexible and robust approach for segmenting cell nuclei from 2D microscopy images using supervised learning and template matching. Cytometry A (2013) 1.23
Segmentation of whole cells and cell nuclei from 3-D optical microscope images using dynamic programming. IEEE Trans Med Imaging (2008) 1.22
CellSegm - a MATLAB toolbox for high-throughput 3D cell segmentation. Source Code Biol Med (2013) 0.97
Tracking epithelial cell junctions in C. elegans embryogenesis with active contours guided by SIFT flow. IEEE Trans Biomed Eng (2014) 0.77
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles. Biochemistry (1974) 6.97
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Cyanine dye labeling reagents: sulfoindocyanine succinimidyl esters. Bioconjug Chem (1995) 3.90
Changes in axon fluorescence during activity: molecular probes of membrane potential. J Membr Biol (1974) 3.80
Changes in absorption, fluorescence, dichroism, and Birefringence in stained giant axons: : optical measurement of membrane potential. J Membr Biol (1977) 3.49
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Spin-labeled mitochondrial lipids in Neurospora crassa. Proc Natl Acad Sci U S A (1968) 3.18
Dye indicators of membrane potential. Annu Rev Biophys Bioeng (1979) 3.14
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Stability, specificity and fluorescence brightness of multiply-labeled fluorescent DNA probes. Nucleic Acids Res (1997) 2.61
A large change in axon fluorescence that provides a promising method for measuring membrane potential. Nat New Biol (1973) 2.37
Improvements in optical methods for measuring rapid changes in membrane potential. J Membr Biol (1981) 2.34
A spin-labeled lipid for probing biological membranes. Chem Phys Lipids (1969) 2.28
Cyanine dye labeling reagents--carboxymethylindocyanine succinimidyl esters. Cytometry (1990) 2.25
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
Mechanisms of rapid optical changes of potential sensitive dyes. Ann N Y Acad Sci (1977) 2.15
A novel fluorescence ratiometric method confirms the low solvent viscosity of the cytoplasm. Biophys J (1993) 2.06
The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem (1981) 2.05
Orientation of lipid spin labels in lecithin multilayers. Proc Natl Acad Sci U S A (1969) 1.91
Evidence for a charge-shift electrochromic mechanism in a probe of membrane potential. Nature (1979) 1.90
Fluorescent probes of biological membranes. Proc Natl Acad Sci U S A (1970) 1.87
Mechanism of potential-dependent light absorption changes of lipid bilayer membranes in the presence of cyanine and oxonol dyes. J Membr Biol (1977) 1.85
The use of cyanine dyes for the determination of membrane potentials in cells, organelles, and vesicles. Methods Enzymol (1979) 1.77
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73
Directly labeled DNA probes using fluorescent nucleotides with different length linkers. Nucleic Acids Res (1994) 1.71
Calcium signals recorded from two new purpurate indicators inside frog cut twitch fibers. J Gen Physiol (1989) 1.67
Cyanine dye labeling reagents for sulfhydryl groups. Cytometry (1989) 1.61
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Cyanine dye labeling reagents containing isothiocyanate groups. Cytometry (1989) 1.51
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51
Structural organization of interphase 3T3 fibroblasts studied by total internal reflection fluorescence microscopy. J Cell Biol (1985) 1.47
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43
Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36
Five-parameter fluorescence imaging: wound healing of living Swiss 3T3 cells. J Cell Biol (1987) 1.33
Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am (1984) 1.30
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26
Properties of new, long-wavelength, voltage-sensitive dyes in the heart. J Membr Biol (2005) 1.26
Cyanine-labeling reagents: sulfobenzindocyanine succinimidyl esters. Bioconjug Chem (1996) 1.23
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22
Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
The spectral properties of some visual pigment analogs. Exp Eye Res (1973) 1.15
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14
Induced optical activity of the metarhodopsins. Biochemistry (1971) 1.11
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 1.09
Cyanine dye dUTP analogs for enzymatic labeling of DNA probes. Nucleic Acids Res (1994) 1.09
Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies. Cancer Immunol Immunother (1995) 1.08
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol (1997) 1.08
A cyanine dye distinguishes between cycling and non-cycling fibroblasts. Nature (1981) 1.07
Leishmania donovani: surface membrane acid phosphatase blocks neutrophil oxidative metabolite production. Exp Parasitol (1985) 1.06
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98
Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology (1984) 0.94
Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun (1984) 0.94
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res (1985) 0.94
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol (1992) 0.93
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol (1993) 0.93
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol (2012) 0.92
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (1990) 0.92
Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. Cancer Res (1980) 0.92
Light-scattering changes during chemotactic stimulation of human neutrophils: kinetics followed by flow cytometry. Cytometry (1985) 0.91
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer (1999) 0.91
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med (1999) 0.90
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol (1997) 0.89
Impermeant potential-sensitive oxonol dyes: I. Evidence for an "on-off" mechanism. J Membr Biol (1988) 0.89
Molecular analysis of melanoma precursor lesions. Cell Growth Differ (1996) 0.89
Molecular mechanism controlling the incorporation of fluorescent nucleotides into DNA by PCR. Cytometry (1997) 0.89
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res (2001) 0.89
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res (1996) 0.89
Impermeant potential-sensitive oxonol dyes: III. The dependence of the absorption signal on membrane potential. J Membr Biol (1988) 0.88
Interferons in melanoma. Curr Opin Oncol (1996) 0.88
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res (1996) 0.88
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol (1984) 0.88
A calcium-sensitive fluorescent analog of calmodulin based on a novel calmodulin-binding fluorophore. J Biol Chem (1990) 0.88
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol (1987) 0.87
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther (2006) 0.87
Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res (1984) 0.86
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep (1984) 0.86
Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med (1988) 0.85
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer (2000) 0.85
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol (2000) 0.84
Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg (1993) 0.84
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol (1987) 0.83
Dysplastic nevi in association with multiple primary melanoma. Cancer Res (1988) 0.83
Imaging cytometry by multiparameter fluorescence. Cytometry (1991) 0.83
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol (1986) 0.83
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev (1984) 0.83
Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res (2000) 0.82
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer (2011) 0.82
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer (1991) 0.82